On August 19, 2026, Indegene Limited, headquartered in Bengaluru, India, announced its authorization to execute a settlement agreement in the TCPA class-action lawsuit filed by Progressive Health and Rehab Corp. The settlement follows a recent Eleventh Circuit decision that has emphasized rigorous scrutiny of TCPA class action settlements, particularly regarding procedural fairness and proportionality of attorney fees to actual relief provided to class members. As per the regulatory filing, the parties have now substantially concluded negotiations on the definitive settlement agreement, with final clarifications made by external counsel on August 18, 2026. The agreement is now awaiting execution by the participating parties and approval from the U.S. District Court. The settlement does not constitute an admission of liability by Indegene, Inc. or its affiliates, and no payment has been made to class members at this stage as the agreement still requires court endorsement.
The proposed settlement provides for a maximum settlement fund of US$4.72 million, calculated at US$250 per eligible claim. However, the $4.72 million represents the contractual maximum and is not the expected cash outflow. The actual payment will depend on the number of valid claims submitted and approved under the settlement framework. The settlement is structured on a claims-made and reversionary basis, meaning Indegene is not required to deposit or pre-fund the entire maximum amount upfront. Instead, actual payments will depend on the number of valid and approved claims submitted by class members. Any amounts not required to satisfy approved claims, along with other payments contemplated under the settlement, will revert to the defendants. The settlement includes an estimated USD 42,559 in administration costs and requires final US District Court approval. Each eligible approved claim is entitled to USD 250 under the settlement agreement guidelines.
The lawsuit, Progressive Health and Rehab Corp. v. Indegene, Inc., concerns alleged violations of the U.S. Telephone Consumer Protection Act, 1991 (TCPA) related to certain fax communications executed in February 2020. In July 2025, the U.S. District Court for the District of New Jersey certified a class comprising approximately 18,851 unique fax numbers, representing 18,869 transmissions. The defendants' petition seeking permission to appeal this certification was denied, leading to mediation and subsequent negotiations. The settlement framework establishes a maximum settlement fund of approximately USD 4.72 million with no upfront funding required. The next steps involve executing the settlement, filing documentation with the court, obtaining preliminary approval, issuing class notices, and conducting claims administration. The company's website will host further information as it becomes available.
The Telephone Consumer Protection Act (TCPA) prohibits automated calls or texts to consumers without prior consent, including calls using prerecorded or synthetic voices, and protects numbers listed on the National Do-Not-Call Registry in the US. When companies violate these rules, affected individuals can pursue statutory damages ranging from $500 to $1,500 per call or text received. The TCPA has increasingly become a focal point for class action litigation, with recent judicial developments highlighting the broader challenges companies face in navigating TCPA-related litigation. As courts continue to refine the boundaries of TCPA enforcement, businesses must remain vigilant in their compliance efforts and strategic in their legal resolutions.
According to Indegene's statement, the company's decision to settle reflects a pragmatic approach to managing legal risk while maintaining business continuity. The company has not indicated whether it will appeal the Eleventh Circuit's recent TCPA-related rulings but has emphasized commitment to legal compliance and stakeholder protection. Indegene serves as the strategic operating partner to the global life sciences industry, orchestrating commercial, medical, R&D, and safety operations across the product lifecycle. The settlement is expected to include provisions for monetary compensation and procedural reforms to prevent future violations. The reversionary nature of the settlement significantly mitigates potential cash outflow, with the absence of upfront funding requirements preserving liquidity while allowing the company to manage cash flows based on actual approved claims rather than worst-case scenarios.
According to Business Standard, Indegene's stock shed 0.66% to currently trade at ₹563.30 on the BSE. The company's net profit remained almost flat at ₹116.2 crore even as revenues rose by 39.7% to ₹1,063.1 crore in Q1 FY27 compared with Q1 FY26. The settlement does not constitute an admission of liability by Indegene or its subsidiary, and the company will assess the accounting impact in accordance with applicable accounting standards once the process concludes.
